This corroborates with findings of Chitnis et al [47] who demonstrated higher dose normalized concentrations of tacrolimus in patients with post-transplant diabetes and the higher risk was observed in subjects with CYP3A5*3 polymorphism. This evidence concerns the gene CYP3A5 and diabetes mellitus.